Cohen's SAC Capital Boosts Stake in United Therapeutics (UTHR) to 7.4%
More News related to UTHR
- United Therapeutics (UTHR) Tops Estimates, Posts Q3 $0.66
- United Therapeutics Corporation Reports Third Quarter 2009 Financial Results
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- United Therapeutics (UTHR) November volatility at 56, January at 43 into EPS
- United Therapeutics Corporation to Announce Third Quarter 2009 Financial Results Before Market Open on Thursday, October 29, 2009
In a 13G filing on United Therapeutics Corp. (Nasdaq: UTHR), Steven Cohen's SAC Capital disclosed a 7.4% stake (1,680,100 shares) in the company. The firm held 372,500 shares in United Therapeutics at the quarter ended June 30, 2008.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases.
SAC is a $14 billion multi-strategy, hedge fund founded by Steven A. Cohen in 1992.
Related Categories
13GsStocks Mentioned
-0.15Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
